RxDoctor Payments Data

Adedoyin Kalejaiye, MD

Otolaryngology · Washington, DCNPI 1063646495

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (52.9%), travel and lodging and education — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Smith+Nephew at 50.0% of the total. Reporting peaked in 2023 at $1,662 and has fallen 78.7% since, to $353 in 2025.

$2,931in general payments, 2019–2025

Across 22 payments — averaging $133.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$1K
  • Stryker$325
  • Medtronic$249
  • Inspire Medical Systems, Inc.$182
  • Aerin Medical Inc.$172
  • Integra Lifesciences Corporation$160
  • plus $377 from 6 others

What the payments were for

  • Travel & lodging$1,33345%
  • Food & beverage$1,55153%
  • Education$472%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,931 in reported general payments places this provider in the 75th percentile of 41 otolaryngology providers in District of Columbia.

See all otolaryngology providers in District of Columbia

Medicare billing

Part B allowed, 2024
$26,797
Medicare patients
125
Services billed
239

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ipratropium Bromide36$696
Fluticasone Propionate35$558

Paid to pharmacies, not to this prescriber.

Other otolaryngology in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →